Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.

about

Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q39570922

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Population pharmacokinetics of ...... d with non-Hodgkin's lymphoma.

@en

Population pharmacokinetics of ...... d with non-Hodgkin's lymphoma.

@nl

type

Item

label

Population pharmacokinetics of ...... d with non-Hodgkin's lymphoma.

@en

Population pharmacokinetics of ...... d with non-Hodgkin's lymphoma.

@nl

prefLabel

Population pharmacokinetics of ...... d with non-Hodgkin's lymphoma.

@en

Population pharmacokinetics of ...... d with non-Hodgkin's lymphoma.

@nl

P1476

Population pharmacokinetics of ...... d with non-Hodgkin's lymphoma.

@en

P2093

Dolores Santos-Buelga

http://www.w3.org/2001/XMLSchema#string

María Del Mar Fernández de Gatta

http://www.w3.org/2001/XMLSchema#string

María José García

http://www.w3.org/2001/XMLSchema#string

P2860

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Use of prior information to stabilize a population data analysis.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.

Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.

P304

1517-1527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13070

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

J M Hernandez

David Martín-García

Jonás Samuel Pérez-Blanco

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27447545

http://www.w3.org/2001/XMLSchema#string

P921

doxorubicinol

P932

5099548

http://www.w3.org/2001/XMLSchema#string